Recruiting
Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants - CV023-005
Actualizada: 22 junio, 2020 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Ubicación (es)
Recruiting
Opciones de tratamiento
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - No clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations - A body mass index of 18 - 32 kg/m2, inclusive - Women and men must agree to follow specific methods of contraception, if applicable For J-MAD Part 3 - Must be Japanese (both biological parents are ethnically Japanese) Exclusion Criteria: - Women who are of childbearing potential - Women who are pregnant or breastfeeding - Any significant acute or chronic medical illness - Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug - Any surgery within 12 weeks of study drug administration Other protocol-defined inclusion/exclusion criteria apply
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
